CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES:
Net income (loss)	$ (6,598)	$ (140,775)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	(6,816)	68,383
Depreciation	17,088	14,351
Amortization of purchased intangible assets and finance leases	10,889	10,799
Amortization of debt issuance costs	2,727	1,885
Change in fair value of contingent consideration	(5,304)	0
Gain on repurchase of convertible notes	(7,200)	0
Allowance for doubtful accounts	1,809	3,477
Gain on divestiture	(17,591)	0
Deferred income taxes	722	926
Equity loss in joint venture	1,384	0
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(20,537)	(32,734)
Prepaid expenses and other current assets	(9,126)	(7,981)
Contract acquisition costs non-current	3,534	(4,758)
Other assets	75	(111)
Accounts payable	(19,757)	6,816
Accrued expenses and other current liabilities	16,737	3,941
Deferred revenue	15,652	13,049
Operating lease liabilities	(437)	(1,721)
Other liabilities	(7,800)	86
Net cash used in operating activities	(30,549)	(64,367)
INVESTING ACTIVITIES:
Purchases of property and equipment, including capitalized software	(16,997)	(25,197)
Payments for acquisitions, net of cash acquired	0	(3,458)
Purchases of intangible assets	(2,457)	(1,129)
Proceeds from divestiture	13,819	0
Investment in joint venture	0	(3,651)
Net cash used in investing activities	(5,635)	(33,435)
FINANCING ACTIVITIES:
Principal payments for financing leases	(1,926)	(1,849)
Proceeds from issuance of common stock in connection with the exercise of options and ESPP	1,256	895
Payments on repurchase of convertible senior notes	(149,702)	0
Net cash used in financing activities	(150,372)	(954)
Effect of foreign exchange rate changes on cash and cash equivalents	789	1,578
Net decrease in cash, cash equivalents, and restricted cash	(185,767)	(97,178)
Cash, cash equivalents, and restricted cash - beginning of year	392,198	523,532
Cash, cash equivalents, and restricted cash - end of period	216,442	426,354
Reconciliation of cash, cash equivalents, and restricted cash to condensed consolidated balance sheets
Cash and cash equivalents	213,763	425,944
Restricted cash	2,679	410
Total cash, cash equivalents, and restricted cash	216,442	426,354
Supplemental disclosure of other cash flow information:
Cash paid for income taxes	1,112	2,237
Cash paid for interest	904	985
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment recorded in accounts payable	581	837
Right of use assets obtained in exchange for operating lease liabilities	132	2,417
Increase in convertible senior notes, net upon adoption of ASU 2020-06 (Note 1)	0	159,407
Issuance of shares of common stock to settle cash awards	0	17,298
WildHealth
Supplemental disclosure of non-cash investing and financing activities:
Issuance of shares of common stock	$ 0	$ 17,675